Scarica l'app Stockscreener
30.37
5.52%
1.59
Dopo l'orario di chiusura:
30.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside Apellis' Strategic Move: New Talent Secured with 7,805 RSU Compensation Package - StockTitan
(APLS) Technical Data - Stock Traders Daily
KBC Group NV Has $3.33 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Cedric Francois Sells 2,824 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock - MarketBeat
Sippican Capital Advisors Sells 9,560 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Morgan Stanley's Strategic Acquisition of Apellis Pharmaceuticals Shares - GuruFocus.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan Sells 546 Shares - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $24,354.00 in Stock - MarketBeat
Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Decreases By 16.0% - MarketBeat
Apellis Pharmaceuticals' (APLS) Sector Perform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel Sells $20,516.40 in Stock - MarketBeat
Apellis Pharmaceuticals chief development officer sells $8,207 in stock - MSN
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock - MSN
Apellis Pharmaceuticals officer sells shares for $10,776 - MSN
Apellis Pharmaceuticals chief development officer sells $8,207 in stock By Investing.com - Investing.com Canada
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
Apellis Pharmaceuticals chief scientific officer sells $24,386 in stock By Investing.com - Investing.com Australia
Apellis Pharmaceuticals general counsel sells $20,518 in stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals CFO sells $16,119 in stock - MSN
Apellis Pharmaceuticals officer sells shares for $10,776 By Investing.com - Investing.com Australia
Apellis Pharmaceuticals CFO sells $16,119 in stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals general counsel sells $20,518 in stock - Investing.com
Sector Update: Health Care -January 28, 2025 at 08:57 am EST - Marketscreener.com
Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA) - Marketscreener.com
Australia approves SYFOVRE as first GA treatment - MSN
Apellis Pharmaceuticals' Geographic Atrophy Treatment Gets Approval From Australian Therapeutic Goods Administration - Marketscreener.com
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA) - The Manila Times
Apellis' SYFOVRE Makes History as First-Ever Geographic Atrophy Treatment in Australia - StockTitan
Apellis Pharmaceuticals CEO Francois sells $412,295 in stock - MSN
Wedbush Predicts Higher Earnings for Apellis Pharmaceuticals - MarketBeat
What is Wedbush’s Forecast for APLS FY2024 Earnings? - Defense World
Merit Financial Group LLC Purchases New Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Apellis Pharmaceuticals VP sells $21,420 in stock - MSN
Have Apellis Pharmaceuticals Insiders Been Selling Stock? - Simply Wall St
Apellis Pharmaceuticals chief scientific officer sells shares worth $120,119 By Investing.com - Investing.com Australia
Apellis Pharmaceuticals' chief people officer sells $53,275 in stock - MSN
Apellis Pharmaceuticals CTO Nicholson Nur sells $120,119 in stock - MSN
Assenagon Asset Management S.A. Sells 2,114,422 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
1.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):